Fir Tree Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Fir Tree Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-635,837	Closed	-$6.42M	–	375
2022 Q4	$6.42M	Sell	635,837 -10,931	-2%	-$109K	0.33%	101
2022 Q3	$6.42M	Hold	646,768	–	–	0.22%	147
2022 Q2	$6.4M	Sell	646,768 -31,453	-5%	-$308K	0.2%	168
2022 Q1	$6.68M	Hold	678,221	–	–	0.19%	170
2021 Q4	$6.67M	Buy	678,221 +275,316	+68%	+$2.7M	0.18%	169
2021 Q3	$3.92M	Buy	402,905 +2,905	+0.7%	+$28.2K	0.13%	219
2021 Q2	$3.87M	Buy	400,000 +100,000	+33%	+$972K	0.15%	193
2021 Q1	$2.91M	Buy	+300,000	New	+$2.91M	0.12%	205

Fir Tree Capital Management's BIOT Position: Q1 2023 in Review

Fir Tree Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 635,837 shares — an estimated $6.42M sold.

Fir Tree Capital Management first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $6.68M in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Fir Tree Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Fir Tree Capital Management sold 635,837 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $6.42M.
Fir Tree Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Fir Tree Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $6.68M in Q1 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Fir Tree Capital Management's 13F filing for Q1 2023, filed 15 May 2023.